contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fleries-portfolio-company-lipum-presents-positive-results-from-its-phase-i-trial-with-sol-116

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine.

InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Flerie

Stockholm, Sweden, April 14, 2025. Flerie AB announces that its portfolio company Lipum has presented final results from a Phase I trial evaluating SOL-116 in healthy volunteers and patients...

<div class="mfn-preamble"><p><strong>Stockholm, Sweden, April 14, 2025. Flerie AB announces that its portfolio company Lipum has presented final results from a Phase I trial evaluating SOL-116 in healthy volunteers and patients with rheumatoid arthritis (RA). A favourable safety profile, predictable pharmacokinetics and confirmed target engagement support further clinical development of SOL-116 as a potential therapy for RA.</strong></p></div><div class="mfn-body"><p>Lipum is developing SOL-116, an innovative biological drug that targets BSSL – a protein involved in inflammation. The drug candidate is primarily being evaluated for the treatment of rheumatoid arthritis, whilst applications for other inflammatory diseases with a high unmet need are also being explored.</p><p>Lipum announced the publication of the Clinical Study Report for its Phase I trial evaluating SOL-116. The study investigated single ascending doses (SAD) and multiple doses (MD) of SOL-116 in healthy volunteers, as well as a single dose in patients with mild rheumatoid arthritis (RA).</p><p>SOL-116 was well tolerated across all dose levels, with no serious adverse events deemed related to the investigational drug. Exploratory results demonstrated reduced levels of BSSL in participants receiving SOL-116, suggesting direct on-target activity. The study also showed predictable pharmacokinetics and anti-drug antibodies (ADA) were detected in only one patient, who reverted to ADA-negative at the subsequent measurement.</p><p>“It is encouraging to see how Lipum is approaching the initiation of a Phase II study. These robust Phase I results strongly support continued development of SOL-116, and as Lipum has GMP manufacturing underway, we are confident that the development will be efficiently executed going forward,” comments Karl Elmqvist, Investment Manager and Head of Flerie’s Product Development segment.</p></div><div class="mfn-footer mfn-contacts mfn-29e5a9386325"><p><strong>For more information:</strong></p><p>Karl Elmqvist<br>Email: ir@flerie.com</p></div><div class="mfn-footer mfn-about mfn-5793c5c817d4"><p><strong class="mfn-heading-1">Flerie in brief</strong><br>Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth&nbsp;opportunities&nbsp;globally alongside other leading investors, focusing predominantly on private&nbsp;companies&nbsp;that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fdd0e220-75b5-4524-9ccc-3d2ab82cb2ec/fleries-portfolio-company-lipum-presents-positive-results-from-its-phase-i-trial-with-sol-116.pdf" class="mfn-generated mfn-primary">Flerie's portfolio company Lipum presents positive results from its Phase I trial with SOL-116</a></p></div>

Flerie's portfolio company Lipum presents positive results from its Phase I trial with SOL-116